Bioidentical Hormones Global Market Report 2024

Bioidentical hormones are identical in chemical structure to those naturally produced by the human body, often used in hormone replacement therapy to address imbalances. They are particularly effective in easing symptoms associated with menopause, andropause, and other hormonal deficiencies, such as hot flashes, night sweats, mood swings, and low libido.

The primary bioidentical hormones include estrogen, progesterone, testosterone, and others. Estrogen, a key female sex hormone, regulates reproductive and secondary sexual characteristics. These hormones are available in various forms such as tablets, capsules, creams, gels, patches, implants, and injectables. They are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels. Applications for bioidentical hormones include managing menopause, hormone replacement therapy (HRT), thyroid disorders, and andropause. They are utilized by diverse end-users such as hospitals, gynecology clinics, research laboratories, and others.

The bioidentical hormones market research report is one of a series of new reports that provides bioidentical hormones market statistics, including bioidentical hormones industry global market size, regional shares, competitors with a bioidentical hormones market share, detailed bioidentical hormones market segments, market trends and opportunities, and any further data you may need to thrive in the bioidentical hormones industry. This bioidentical hormones market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bioidentical hormones market size has grown strongly in recent years. It will grow from $7.05 billion in 2023 to $7.49 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. During the historical period, growth can be linked to heightened awareness of hormone-related health issues, an increase in hormonal imbalances, a growing elderly population, rising healthcare expenditure, and greater demand for alternative medicine.

The bioidentical hormones market size is expected to see strong growth in the next few years. It will grow to $9.6 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. Anticipated growth in forecast period is driven by a rising emphasis on women's health, expanding acceptance of personalized medicine, supportive governmental policies, rising incidence of chronic diseases, and increasing awareness of bioidentical hormones' advantages. Key trends expected in the forecast period include the development of innovative bioidentical hormone formulations, greater use of telemedicine for hormone therapy consultations, increased integration of bioidentical hormones into mainstream medical practices, advancements in hormone delivery systems, and the growing influence of biotechnology on hormone production.

The increasing demand for personalized medicine is anticipated to drive the growth of the bioidentical hormones market. Personalized medicine involves customizing medical treatment based on individual characteristics, such as genetics or lifestyle, to enhance effectiveness and reduce adverse effects. This growing demand stems from its potential to offer more effective treatments, advancements in genomics, increasing disease complexity, and regulatory support. Bioidentical hormones align with personalized medicine by matching a patient's specific hormonal profile, improving treatment efficacy, and minimizing side effects. For instance, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. Thus, the rising demand for personalized medicine is fueling the bioidentical hormones market.

Leading companies in the bioidentical hormones market are focusing on developing advanced solutions such as bioidentical hormone replacement therapy (BHRT) to provide more effective and personalized treatments for hormonal imbalances and related health conditions. BHRT uses hormones that are chemically identical to those produced by the human body to address hormone imbalances and associated symptoms. For example, in May 2024, Jagsonpal Pharmaceuticals Limited, an Indian pharmaceutical company, launched MemUp HRT, a US FDA-approved bioidentical hormone therapy. This therapy features a single-pill solution combining bioidentical estradiol and progesterone, with support available in nine regional languages. This launch aims to leverage bioidentical hormones for balanced hormone replacement and improve patient compliance, thereby raising awareness about menopause management, enhancing patient outcomes, and expanding healthcare options for women in India.

In January 2024, BioTE Medical, LLC, a US-based healthcare company, acquired Asteria Health for $8.5 million. This acquisition strengthens BioTE's supply chain, enhances manufacturing capabilities, and improves its margin profile, positioning BioTE as a vertically integrated leader in the bioidentical hormones market and ensuring reliable access to innovative therapeutic wellness solutions. Asteria Health, based in the UK, provides pharmaceutical compounding solutions, including compounded bioidentical hormones.

Major companies operating in the bioidentical hormones market are Pfizer Inc., AbbVie Inc., Bayer AG, Abbott Laboratories Inc., Merck KGaA, Hikma Pharmaceuticals Plc, TherapeuticsMD Inc., Gedeon Richter Plc, Noven Pharmaceuticals Inc., AnazaoHealth Corp., Women's International Pharmacy Inc., Wells Pharmacy Network, ZRT Laboratory LLC, BionPharma Inc., Orion Pharma AB, Actiza Pharmaceutical Private Limited, Biostation, Advantage Pharmaceuticals Inc., Bravado Labs, Neuva Aesthetics, Papillon Medical, United Pharmacy LLC, SottoPelle Inc., Apotheca Compounding Pharmacy, MedQuest Pharmacy.

North America was the largest region in the bioidentical hormones market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioidentical hormones market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the bioidentical hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bioidentical hormones market includes revenues earned by entities by providing services such as personalized hormone level testing, compounding pharmacy services, anti-aging treatments, wellness and longevity programs, weight management support, and integrative health services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.